Immunosuppression Strategies in Liver Transplantation

Liver transplantation represents a life-saving intervention for end‐stage liver disease, yet long-term graft survival hinges on effective immunosuppression. Standard regimens centre on calcineurin inhibitors to prevent T-cell activation, often combined with corticosteroids and induction agents to reduce early rejection. However, prolonged use of calcineurin inhibitors can lead to nephrotoxicity, hypertension and metabolic complications. To mitigate these risks, minimisation protocols incorporate mammalian target of rapamycin inhibitors or antimetabolites, aiming to preserve graft function while limiting adverse effects. Emerging approaches seek to personalise therapy through non-invasive biomarkers, allowing stratification of patients according to immunological risk and guiding gradual tapering or withdrawal in those achieving operational tolerance. Concurrently, advances in understanding the intrahepatic immune milieu have revealed roles for regulatory T cells, macrophage subsets and immune exhaustion pathways in shaping graft acceptance or rejection. Translational research is now exploring targeted immunotherapies and tolerance induction strategies—such as co-stimulation blockade and cell-based therapies—to achieve durable graft protection with minimal lifelong medication burden. This evolving landscape underscores the global imperative to balance rejection prophylaxis with quality of life and long-term patient outcomes.

Research from Nature Portfolio

A recent study evaluated non-invasive detection of subclinical graft injury by measuring donor-specific anti-HLA antibodies (DSA) alongside other plasma markers in clinically stable liver transplant recipients. While a cell-death biomarker showed limited diagnostic value, DSA positivity strongly correlated with histological inflammation and fibrosis. Importantly, absence of DSA accurately predicted suitability for immunosuppression minimisation in the majority of patients, whereas DSA positivity identified individuals requiring closer surveillance or biopsy. These findings support incorporation of DSA screening into routine follow-up to individualise tapering schedules and reduce unnecessary drug exposure.

Immunosuppression Strategies in Liver Transplantation publication trend

The graph below shows the total number of articles in immunosuppression strategies in liver transplantation across all publications each year (not limited to Nature Index journals).

Technical terms

Calcineurin inhibitors (CNIs): Drugs (e.g., tacrolimus, ciclosporin) that block T-cell activation by inhibiting the phosphatase calcineurin, widely used to prevent acute rejection but associated with nephrotoxicity and metabolic side effects.

mTOR inhibitors: Agents (e.g., everolimus, sirolimus) targeting the mammalian target of rapamycin pathway to inhibit lymphocyte proliferation, often used to reduce CNI exposure and preserve renal function.

Induction therapy: Short-term, high-intensity immunosuppression (e.g., lymphocyte-depleting antibodies) administered at the time of transplantation to prevent early acute rejection.

Donor-specific antibodies (DSA): Recipient antibodies directed against donor HLA antigens, serving as biomarkers for alloimmune activation, risk of rejection and suitability for immunosuppression minimisation.

Regulatory T cells (Tregs): A subset of CD4+ T lymphocytes that suppress immune responses and promote tolerance to the graft, critical for long-term acceptance without excessive immunosuppression.

Immune exhaustion: A state of functional impairment in T cells characterised by upregulation of inhibitory receptors (e.g., PD-1), which may limit alloimmune damage but also affect response to immunotherapeutic strategies.

References

1. Spatially resolved immune exhaustion within the alloreactive microenvironment predicts liver transplant rejection. Science Advances (2024).
2. The Immunological Basis of Liver Allograft Rejection. Frontiers in Immunology (2020).
3. A Comprehensive Review of Immunosuppression Used for Liver Transplantation. Journal of Transplantation (2009).
4. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. Hepatology International (2020).
5. Non-invasive screening for subclinical liver graft injury in adults via donor-specific anti-HLA antibodies. Scientific Reports (2020).